An observational study in Genetic Disease and Aneuploidy, sponsored by Istituto Clinico Humanitas. Completed. Open to female participants aged 34 Years to 42 Years. Per ClinicalTrials.gov, last updated 2023-07-10.
Sponsored by Istituto Clinico Humanitas · Observational
This monocentric retrospective observational study aims to evaluate the efficacy of pre-implantation genetic testing for monogenic diseases (PGT-M). The effectiveness will be assessed in terms of live birth rate (LBR), cumulative live birth rate (CLBR) per couple, and abortion rate (AR). Considering how many cycles the participants have undergone to achieve a viable blastocyst. The secondary objective is to evaluate the incidence of aneuploidy in unaffected embryos, in order to understand the need for pre-implantation genetic testing for aneuploidy (PGT-A)in addition to PGT-M.
All 76 participants that underwent PGTM testing in the Fertility Center starting from the beginning of 2016 all through the end of 2022, will be included in the study.
Exclusion Criteria:
Live birth rate (LBR)
LBR will be measured as a percentage
Time frame: 7 years of inclusion
Cumulative live birth rate (CLBR) per couple
CLBR per couple will be measured as a percentage
Time frame: 7 years of inclusion
Abortion rate (AR)
AR will be measured as a percentage
Time frame: 7 years of inclusion
Aneuploidy
Aneuploidy embryo rate will be measured as a percentage
Time frame: 7 years of inclusion
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Clinico Humanitas